The Future of Obesity Treatment: Beyond GLP-1 Receptor Agonists The landscape of obesity pharmacotherapy is shifting from broad-spectrum hormonal treatments toward targeted therapies designed to preserve muscle mass while reducing …
Tag:
Semaglutid
-
-
Orforglipron, an experimental oral GLP-1 receptor agonist, demonstrates potential for long-term weight maintenance in patients transitioning from injectable therapies, according to phase 3b trial data. Results presented in May 2026 …
-
The Future of Weight Management: How Genetics and the Microbiome Influence Long-Term Success For millions struggling with obesity, the arrival of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and …